Header Logo

Connection

CHAD CREIGHTON to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications CHAD CREIGHTON has written about Breast Neoplasms.
CHAD CREIGHTON
Connection Strength
4.229
Breast Neoplasms
  1. An essential gene signature of breast cancer metastasis reveals targetable pathways. Breast Cancer Res. 2024 06 12; 26(1):98.
    View in: PubMed
    Score: 0.356
  2. Gene Expression Profiles in Cancers and Their Therapeutic Implications. Cancer J. 2023 Jan-Feb 01; 29(1):9-14.
    View in: PubMed
    Score: 0.322
  3. Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors. PLoS One. 2013; 8(12):e71158.
    View in: PubMed
    Score: 0.172
  4. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 04; 490(7418):61-70.
    View in: PubMed
    Score: 0.158
  5. A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat. 2012 Apr; 132(3):993-1000.
    View in: PubMed
    Score: 0.145
  6. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
    View in: PubMed
    Score: 0.135
  7. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010 Jun; 15(2):253-60.
    View in: PubMed
    Score: 0.133
  8. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5.
    View in: PubMed
    Score: 0.127
  9. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.
    View in: PubMed
    Score: 0.120
  10. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008 Sep 01; 26(25):4078-85.
    View in: PubMed
    Score: 0.119
  11. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
    View in: PubMed
    Score: 0.116
  12. A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. BMC Genomics. 2007 Jun 28; 8:199.
    View in: PubMed
    Score: 0.110
  13. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene. 2007 Jul 12; 26(32):4648-55.
    View in: PubMed
    Score: 0.106
  14. Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol. 2006; 7(4):R28.
    View in: PubMed
    Score: 0.101
  15. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006 Apr 01; 66(7):3903-11.
    View in: PubMed
    Score: 0.101
  16. When will tumor gene expression profiling be incorporated into clinical breast cancer decision making? Breast Cancer Res. 2006; 8(4):302.
    View in: PubMed
    Score: 0.099
  17. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022 11; 41(48):5214-5222.
    View in: PubMed
    Score: 0.079
  18. Noncanonical Wnt/Ror2 signaling regulates cell-matrix adhesion to prompt directional tumor cell invasion in breast cancer. Mol Biol Cell. 2022 09 15; 33(11):ar103.
    View in: PubMed
    Score: 0.079
  19. Functional Hierarchy and Cooperation of EMT Master Transcription Factors in Breast Cancer Metastasis. Mol Cancer Res. 2021 05; 19(5):784-798.
    View in: PubMed
    Score: 0.070
  20. Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression. Oncogene. 2019 08; 38(31):5942-5958.
    View in: PubMed
    Score: 0.063
  21. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep. 2018 08 07; 24(6):1434-1444.e7.
    View in: PubMed
    Score: 0.059
  22. Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. PLoS One. 2018; 13(3):e0194913.
    View in: PubMed
    Score: 0.058
  23. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292.
    View in: PubMed
    Score: 0.058
  24. Coactivation of Estrogen Receptor and IKK? Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer. Cancer Res. 2018 02 15; 78(4):974-984.
    View in: PubMed
    Score: 0.057
  25. Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. Oncogene. 2017 10 26; 36(43):5958-5968.
    View in: PubMed
    Score: 0.055
  26. A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis. Neoplasia. 2017 May; 19(5):421-428.
    View in: PubMed
    Score: 0.054
  27. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Apr 01; 35(10):1061-1069.
    View in: PubMed
    Score: 0.053
  28. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
    View in: PubMed
    Score: 0.052
  29. Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis. 2016 Dec; 37(12):1180-1189.
    View in: PubMed
    Score: 0.052
  30. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
    View in: PubMed
    Score: 0.050
  31. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. Cancer Res. 2015 Dec 15; 75(24):5341-54.
    View in: PubMed
    Score: 0.049
  32. Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep. 2015 Jul 21; 12(3):511-24.
    View in: PubMed
    Score: 0.048
  33. Reverse phase protein arrays in signaling pathways: a data integration perspective. Drug Des Devel Ther. 2015; 9:3519-27.
    View in: PubMed
    Score: 0.048
  34. Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer. Cell Death Dis. 2015 Mar 19; 6:e1699.
    View in: PubMed
    Score: 0.047
  35. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
    View in: PubMed
    Score: 0.046
  36. In-silico QTL mapping of postpubertal mammary ductal development in the mouse uncovers potential human breast cancer risk loci. Mamm Genome. 2015 Feb; 26(1-2):57-79.
    View in: PubMed
    Score: 0.046
  37. KAP1 promotes proliferation and metastatic progression of breast cancer cells. Cancer Res. 2015 Jan 15; 75(2):344-55.
    View in: PubMed
    Score: 0.046
  38. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.045
  39. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
    View in: PubMed
    Score: 0.044
  40. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402.
    View in: PubMed
    Score: 0.044
  41. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 2015 Mar 12; 34(11):1341-53.
    View in: PubMed
    Score: 0.044
  42. Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.
    View in: PubMed
    Score: 0.043
  43. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2013 Apr; 138(2):369-81.
    View in: PubMed
    Score: 0.041
  44. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Res Treat. 2012 Jul; 134(2):583-93.
    View in: PubMed
    Score: 0.039
  45. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(2):531-41.
    View in: PubMed
    Score: 0.038
  46. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
    View in: PubMed
    Score: 0.037
  47. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.
    View in: PubMed
    Score: 0.036
  48. Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011 Oct 27; 30(43):4399-409.
    View in: PubMed
    Score: 0.036
  49. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.
    View in: PubMed
    Score: 0.035
  50. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
    View in: PubMed
    Score: 0.035
  51. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
    View in: PubMed
    Score: 0.029
  52. MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. 2007 Jul; 104(1):13-9.
    View in: PubMed
    Score: 0.026
  53. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade. Nat Commun. 2022 01 11; 13(1):245.
    View in: PubMed
    Score: 0.019
  54. HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.
    View in: PubMed
    Score: 0.012
  55. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 2014 Feb 15; 20(4):962-71.
    View in: PubMed
    Score: 0.011
  56. CCAAT/enhancer binding protein beta regulates stem cell activity and specifies luminal cell fate in the mammary gland. Stem Cells. 2010 Mar 31; 28(3):535-44.
    View in: PubMed
    Score: 0.008
  57. SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. J Biol Chem. 2010 Feb 05; 285(6):3608-3616.
    View in: PubMed
    Score: 0.008
  58. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 2009 Jun 15; 15(12):3979-89.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.